Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules

Executive Summary

CEO Michael Gilman, who now helms the company full time, said Arrakis will use its Series B venture capital funding to build a pipeline of drug candidates, primarily in cancer, with the goal of taking its first medicines into the clinic in the next two to three years.
Advertisement

Related Content

Venture Funding Deals: CNS Plays Are Attracting Investment
Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver
Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout
Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells
With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules
Value Unlocked: BMS Buying Padlock For Up To $600m
'Welcome home': Stromedix buy brings fibrosis drug back to Biogen

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125092

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel